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Alternative splicing (AS) is a common posttranscriptional process in eukaryotic organisms, by which multiple distinct functional
transcripts are produced from a single gene. The release of the human genome draft revealed a much smaller number of genes
than anticipated. Because of its potential role in expanding protein diversity, interest in alternative splicing has been increasing
over the last decade. Although recent studies have shown that 94% human multiexon genes undergo AS, evolution of AS and thus
its potential role in functional innovation in eukaryotic genomes remain largely unexplored. Here we review available evidence
regarding the evolution of AS prevalence and functional role. In addition we stress the need to correct for the strong eﬀect of
transcript coverage in AS detection and set out a strategy to ultimately elucidate the extent of the role of AS in functional innovation
on a genomic scale.
1. Introduction
The first draft of the human genome sequence [1, 2] was
unveiled in February 2001 and surprisingly it was shown to
contain ∼23000 genes, only a fraction of the numbers of
genes originally predicted [3]. To put this into perspective,
there are ∼20,000 genes in the genome of the nematode C.
elegans. The lack of an association between gene number and
organismal complexity has resulted in an increased interest
in alternative splicing (AS) given it has been proposed to be
a major factor in expanding the regulatory and functional
complexity, protein diversity, and organismal complexity of
higher eukaryotes [4–6]. However, despite the best eﬀorts
of many research groups we still understand very little
about the actual role played by AS in the evolution of
functional innovation—here understood as the appearance
of novel functional transcripts—underpinning the increased
organismal complexity observed.
Alternative splicing is a posttranscriptional process in
eukaryotic organisms by which multiple distinct transcripts
are produced from a single gene [4]. Previous studies using
high-throughput sequencing technology have reported that
up to 92%∼94% of human multiexon genes undergo AS
[7, 8], often in a tissue/developmental stage-specific manner
[7, 9]. With the development and constant improvement
of whole genome transcription profiling and bioinformatics
algorithms, the ubiquity of AS in the mammalian genome
began to become clear. The concept of one gene-one protein
gave way as evidence mounted for the high percentage of
AS incidence in nonhuman species [7, 8], such as fruit
fly [10], Arabidopsis [11] and other eukaryotes [5]. Despite
the advances in our understanding and characterisation
of AS several questions remain unanswered. First, the
large diﬀerence in transcript coverage between species has
hampered direct comparisons of the prevalence of alternative
splicing in diﬀerent species [6]. Secondly, even if comparable
AS estimates between species could be obtained, it is
unclear to what extent any changes in AS prevalence along
evolution have contributed to overall protein diversity or
rather reflect splicing noise. Finally, we understand very
little about how AS has evolved through time and how
this is related to functional parameters of genes. Here we
review how alternative is regulated and recent progress in our
understanding of the evolution of alternative splicing.
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2. Alternative Splicing and Its Regulation
In 1977, Chow et al. [12–15] reported that 5′ and 3′ terminal
sequences of several adenovirus 2 (Ad2) mRNAs varied,
implying a new mechanism for the generation of several
distinct mRNAs. Following this study, alternative splicing
was also found in the gene encoding thyroid hormone
calcitonin in mammalian cells. Subsequent studies revealed
that many other genes were also able to generate more
than one transcript by cuttingout diﬀerent sections from its
coding regions (reviewed in [4, 16]).
Depending on the location of the exonic segments cut-
out-or if introns are left in, splicing events can be classified
into four basic types (Figure 1). These four major modes
of splicing are (1) exon skipping (2) intron retention (3)
alternative 5′ splicing site (5′ss), and (4) alternative 3′
splicing site (3′ss) [22, 23]. In addition, mutually exclusive
exons, alternative initiation, and alternative polyadenyla-
tion provide two other mechanisms for generating various
transcript isoforms. Moreover, diﬀerent types of alternative
splicing can occur in a combinatorial manner and one exon
may be subject to more than one AS mode, for example,
5′ss and 3′ss at the same time (Figure 1). Prevalence of each
type of AS has been found to vary between diﬀerent taxa.
Several studies have shown that exon skipping is common in
metazoan genomes [24] whereas intron retention is the most
common type of AS among plants [25] and fungi [26].
Alternative splicing is tightly regulated by cis elements
as well as transacting factors that bind to these cis elements.
Transacting factors, mainly RNA-binding proteins, modulate
the activity of the spliceosome and cis elements such as
exonic splicing enhancers (ESEs), exonic splicing silencers
(ESSs), intronic splicing enhancers (ISEs), and intronic
splicing silencers (ISSs). Canonical mechanism of AS sug-
gests that serine/arginine-rich (SR) proteins typically bind
to ESEs, whereas heterogeneous nuclear ribonucleoproteins
(hnRNP) tend to bind to ESSs or ISSs [27]. Given the crucial
roles of these regulators in the splicing machinery, the cis
and transacting mutations, which disrupt the splicing code,
are known to cause disease (reviewed in [28–30]) . It has
been estimated that 15–60% of mutations cause disease by
aﬀecting the splicing pattern of genes ([31] and reviewed in
[30]). Moreover, AS has also been shown to be regulated
without the involvement of auxiliary splicing factors [32]
and AS may be also combined with other posttranscriptional
events such as the use of multiple internal translation
initiation sites, RNA editing, mRNA decay, and microRNA
binding and other noncoding RNAs [33, 34], suggesting the
existence of additional noncanonical mechanism of AS that
are yet to be identified [35].
Recently, a direct role of histone modifications in
alternative splicing has been reported, in which histone
modification (H3-K27m3) aﬀects the splicing outcome by
influencing the recruitment of splicing regulators via a
chromatin-binding protein in a number of human genes
such as FGFR2,TPM2,TPM1 and PKM2 [36]. Moreover, it
has been reported that CTCF-promoted RNA polymerase
II pausing links DNA methylation to splicing, providing
the first evidence of developmental regulation of splicing
outcome through heritable epigenetic marks [37]. Addi-
tionally, non-coding RNAs also have emerged as key deter-
minants of alternative splicing patterns [34]. Therefore
these findings reveal an additional epigenetic layer in the
regulation of transcription and alternative splicing [38].
Genomewide genetic and epigenetic studies, therefore, have
been proposed in at least 100 specific blood cell types [39],
which will provide high quality reference epigenomes (using
DNA methylation and histone marks assays) with detailed
genetic and transcriptome data (whole genome sequencing,
RNA-Seq, and miRNA-Seq), providing us with an opportu-
nity to assess the genomewide influence of epigenetic factors
in the regulation of AS in specific blood cell types. We are
expecting the rise of comparative epigenetics will provide
diﬀerent perspective of the evolution of transcriptome.
3. Identification of
Alternative Splicing Events
Alternative splicing is diﬃcult to estimate from genomic
parameters alone [40]. A number of regulatory motifs
for AS have been uncovered but the presence of known
alternative splicing motifs does not guarantee that a gene is
actually alternatively spliced [40]. Thus, alternative splicing
patterns are generally assessed from examining transcript
data. For any gene of interest, alternative splicing events
can be identified by using reverse transcription polymerase
chain reaction (RT-PCR) conducted on a complementary
DNA (cDNA) library. Over the last decade, as high-
throughput transcriptome technologies have improved, it
has become possible to assess alternative splicing patterns on
a genomewide scale. Three main sources of transcriptome
data have been used to assess splicing patterns: expressed
sequence tags (ESTs), splice-junction microarrays, and RNA
sequencing (RNA-Seq).
The first wave of genomewide transcriptome analysis
consisted in direct sequencing cDNA and ESTs carried out
at large scale [41], which allowed alternative splicing events
to be identified by aligning cDNA/EST sequences to the
reference genome. ESTs are 200–800 nucleotide bases in
length, unedited, randomly selected single-pass sequence
reads derived from cDNA libraries [42]. Currently, there are
eight million ESTs for human, including about one million
sequences from cancer tissues, and about 71 million ESTs
for around 2000 species in dbEST [43]. However, ESTs
are based on low-throughput Sanger sequencing and are
aggregated over a wide range of tissues, developmental states,
and diseases using widely diﬀerent levels of sensitivity.
More recently, splice-junction microarrays and RNA-Seq
have been increasingly used to quantitatively analyse alterna-
tive splicing events. Splicing microarrays target specific exons
or exon-exon junctions with oligonucleotide probes. The
fluorescent intensities of individual probes reflect the relative
usage of alternatively splicing exons in diﬀerent tissues and
cell lines [44]. High-density splice-junction microarrays are
a cost-eﬀective way to assay previously known exons and
AS events with low false positive rate. The disadvantage
is that it requires prior knowledge of existing AS variants
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Figure 1: Diﬀerent types of alternative splicing. The blue boxes are constitutive exons and alternatively spliced regions in red. Introns are
represented by straight lines between boxes. Four types of common splicing events were identified: (1) exon skipping (2) intron retention
(3) alternative 5′ splicing site (5′ss), and (4) alternative 3′ splicing site (3′ss).
and gene structures. More importantly unlike RNA-Seq
and EST, microarrays do not provide additional sequence
information.
RNA-Seq has emerged as a powerful technology for
transcriptome analysis due to its ability to produce millions
of short sequence reads [45–47]. RNA-Seq experiments pro-
vide in-depth information on the transcriptional landscape
[45]. The ever-increasing accumulation of high-throughput
data will continue to provide ever richer opportunities to
investigate further aspects of AS such as low-frequency AS
events as well as tissue-specific and/or development-specific
AS events [7, 8, 47–49]. Earlier datasets consist of RNA read
sequences of 50 bp or less, limiting the information about
combinations of AS events in a single transcript but it is
likely that the length of short reads will continue to increase
over the next decade. With the increasing capacity of next-
generation sequencing (RNA-Seq) the study of alternative
spicing is likely to undergo a revolution [50]. The higher
depth of sequencing of transcriptomes in human and other
species has increased our understanding of the occurrence
of AS event and AS expression patterns in diﬀerent tissues
[7, 51], developmental stages [10].
Transcript assembly of sequence-based technologies,
such as ESTs and RNA-Seq, can use either align-then-
assemble or assemble-then-align, depending on the quality
of reference genome and sequence data [47]. An algorithm
can be employed to detect AS event by comparing diﬀerent
transcripts. However, detecting AS isoforms, as opposed to
single AS event, is still challenging because short sequences
provide little information in terms of the combination
of exons. Several applications have been developed for
transcript assembly and AS isoform detection, diﬀerent
strategies and comparison of these applications have been
reviewed previously [47].
4. Prevalence of Alternative Splicing across
Eukaryotic Genomes
Initial whole genome analyses suggested that 5%–30% of
human genes were alternatively spliced (reviewed in [6, 16]).
EST-based AS databases identify AS events in 40–60% of
human genes [5, 52, 53]; however, recently this number has
been revised over and over with the latest estimates showing
that up to 94% of human multiexon genes produce more
than one transcript through alternative splicing [7, 8, 16].
Understanding how alternative splicing has changed over
time could provide insights as to how alternative splicing has
impacted on transcript and protein diversity and phenotype
evolution [6]. In fungi, AS is thought to be rare due to
the low number of exons in yeast [23]. In plants it has
been estimated that around 20% of genes undergo AS
based on EST data [25], a recent study using RNA-Seq,
however, suggests that at least approximately 42% of intron-
containing genes in Arabidopsis are alternatively spliced [11].
We are expecting significantly higher percentages of AS
occurrence will be discovered from various eukaryotes given
the in-depth studies of transcriptome using next-generation
sequencing such as RNA-Seq are ongoing. A few studies have
attempted to compare AS prevalence among diﬀerent taxa
with animals generally reported to have higher AS incidence
than plants [16] and vertebrates having a higher AS incidence
than invertebrates [24]. However, these studies are either
based on limited data or failed to correct for diﬀerences in
transcript coverage [6].
There are a number of databases that provide AS data for
multiple species [5, 52–54]. However, these existing resources
are primarily focused on animal species and have poor
coverage for protist, fungal, and plant genomes thus making
it diﬃcult to compare divergent taxa.Most importantly, none
of these resources take into account the well-documented
eﬀects of diﬀerential transcript coverage across genes within
and between species which greatly influences AS detection
rates [6, 24, 55, 56]. Random sampling has been used [24]
and shown to minimize the bias of transcript coverage
(Figure 2). We expect that similar strategies will be employed
in future comparative AS data resources.
5. Is Alternative Splicing Functional
or Mostly Just Noise?
If an increase in AS levels in vertebrate species compared to
invertebrates is confirmed, given the limitations of current
proteomics resources, it is hard to assess the extent to
which alternatively spliced transcripts are translated into
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Figure 2: Total transcript number influences AS detection but bias
can be corrected by using a sampling method. AS detection in genes
divided by transcript coverage for the nematode (a and b) using the
full transcript dataset (a) or a random sampling method (b).
an expanded proteome. The evolution of many phenotypes
that we most associate with human being such as longer
lifespan, encephalization, or even increased complexity
have been accompanied by sharp reductions in eﬀective
population size, possibly explaining the proliferation of a
variety of genomic features in more complex organisms
([57] but see [58]). Therefore, it is possible that increased
AS through evolution results from aberrant splicing and
therefore it does not play any functional role [59–61]. If
alternative splicing has increased along the phylogenetic
tree and it is indeed functional, we can expect the follow-
ing.
(A) Transcripts should have a low incidence of premature
stop codons which would render them vulnerable to
nonsense mediated decay. Between 4% and 35% of
AS human transcripts have been found to contain a
premature termination codon in human and mouse
transcripts [62, 63]. These transcripts have been
found to be enriched in nonconserved exons likely to
cause frame shifts [64]. It is unknown whether the
proportion of premature stop codon containing AS
transcripts has changed along the phylogenetic tree.
(B) It has been proposed that most low copy number
alternative isoforms produced in human cells are
likely to be nonfunctional [65, 66]. A recent study
has shown that although cancer-specific alternative-
splicing variants can be found, these events are
mostly found as single-copy events and thus unlikely
to contribute to the core cancer transcriptome [67].
(C) Conservation of alternative-splicing events along
evolution can be taken as an indicator of their
functional role. Conservation levels of AS have been
studied in many species. The estimation ranges from
11% to 67% between human and mouse [68–70].
Notably, major AS forms tend to be have higher
conservation levels compared to minor forms. On
the other hand, the conserved AS forms vary among
diﬀerent AS; for example, exon skipping between
C. elegans and C. briggsae has shown more than
81% conservation level, compared to 28% for intron
retention [71, 72].
(D) Presence of identifiable functional domains in AS
areas may also be an indicator of functional relevance
for AS transcripts [67]. To our best knowledge
there are no reports of the prevalence of functional
domains in AS areas in model species. To examine the
presence of functional domains in AS transcripts, we
compiled a set of 267,996 AS events obtained from
the analysis of 8,315,254 ESTs from normal human
tissues. We found that about 50% of AS areas in
human contain known functional components using
InterProScan [17] which contains 14 applications
for the prediction of protein domains (Figure 3, see
methods in [67]), suggesting a possible functional
role for AS. The extent of the variations in the
prevalence of functional domains among AS areas
between species remains to be explored but would
provide additional insights on the evolution of AS.
Taken together above observations suggest that although
alternative splicing-events are indeed conserved throughout
evolution a significant proportion are not and some may
result from noisy transcript splicing not contributing to
the protein pool. However, until further studies using
comparable AS indexes it will be impossible to estimate the
extent to which increases in AS levels along the phylogenetic
tree have impacted on the pool of functional transcripts.
6. Alternative Splicing and Gene Duplication
Gene duplication (GD) is considered a prime source of
functional innovation in the genome. Newly duplicated
genes can evolve functional divergence [73], and it is thought
to be key in driving the evolution of developmental and
morphological complexity in vertebrates [74]. Alternative
splicing, as a prevalent mechanism that also increases protein
diversity, has been proposed as a potential player in the
evolution of eukaryotes [4, 6]. By examining the relationship
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Transmembrane domains 1%
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Figure 3: Percentage of AS areas containing identifiable func-
tional domains, secondary structures, and stop codons in human.
Functional components were identified using InterProScan which
contains 14 applications for the prediction of protein domains
[17], including Pfam for the prediction of protein domains [18],
SignalP 3.0 for signal peptide predictions [19], and TMHMM [20]
for the predictions of transmembrane domains. PSORT II [21]
was used to identify the likely subcellular localization of protein
products. Secondary protein structures were predicted by CLC
MainWorkbench 5.7, which is based on extracted protein sequences
from the protein databank (http://www.rcsb.org/pdb/).
between gene duplication and alternative splicing we can
better understand the extent to which both mechanisms
are equivalent means for protein diversification. Several
studies have reported a negative correlation between AS
and gene family size in human and mouse [6, 65, 75,
76] and worm [71, 77] (Table 1). It is easy to lead to a
conclusion that AS and GD are interchangeable and there
is a universal negative correlation from worm to human.
However, the relationship between the two variables is
marginal at best and it is not consistent when including
singleton genes which have a lower AS level compared to
multigene families [76, 78, 79]. Jin et al. [76] suggested
that singletons have more evolutionary constriction than
duplicates which hampers their AS isoform gain Consistent
with this hypothesis, Lin et al. [78] found that singletons
diﬀer from multigene families in several aspects suggesting
that they have diﬀering evolutionary paths. Even if we focus
on multigene families only, a negative correlation between
AS and gene family size may be explained or byproduct
of AS and gene family size covariance with other factors.
For example, gene age and biased duplication have been
proposed to be the explanation [79]. This study has cast
doubt over the relationship between AS and GD and it may
indeed provide support to the suggestion that AS and GD
have little or no equivalence concerning eﬀects on protein
sequence, structure, and function [80]. As most studies have
examined a small number of model species it is diﬃcult to
assess the extent of the link between AS and GD. In addition,
the snapshot approach of comparing GFS and AS in a single
genome might hide the true relationship between AS and
GFS.
(a) Splicing signal degeneration
(b) Exonization of non-coding DNA or transposons
Exon
Intron
Degenerate splicing signal
New exon
Duplicated exon
AS regulatory region cell type A
AS regulatory region cell type B
Cell type A
Cell type B
(c) Exon duplication and specialization of isoforms
Figure 4: Novel AS variants can take on specialised or novel roles.
Novel splicing variants can arise from (a) mutations in the exon
recognition site of a constitutive exon and subsequent acquisition
of AS regulatory elements. (b) Exonization of introns or intron
regions or transposable elements with subsequent acquisition of
AS regulatory regions. Novel proteins may interact with diﬀerent
proteins or localise in diﬀerent subcellular regions. (c) Exon
duplication and subsequent specialization functional domains and
AS regulatory regions. Resulting specialised proteins may take on
partial roles relevant in diﬀerent cell types or developmental stages
or result in novel interactions and functions.
7. Alternative Splicing’s Contribution to
Functional Innovation
Alternative splicing has been hailed as the missing source
of information in the genome accounting for the evolution
of higher complexity despite the near static gene number
in metazoans over the last 800 million years. Wegmann et
al. [81] found that width of gene expression is positively
6 International Journal of Evolutionary Biology
Table 1: Summary for the relationship between AS and GFS.
Species Data Alternative splicing Orthology Bias control Correlation Reference
Human
Ensembl
ASD’s AltSplice
database
BLSATP
Exons, EST coverage, gene
family size, isoform count
Negative correlation [75]
NCBI, UCSC
GeneSplicer
program
EnsMart
Remove garbage EST, EST
coverage,
Negative correlation [65]
H-InvDB 5.0 H-InvDB 5.0 BLAST
Positive correlation when
includes all gene fami-
lies. Negative correlation
within multigene families
[76]
Mouse
Ensembl
ASD’s AltSplice
database
BLSATP
Exons, EST coverage, gene
family size, isoform count
Negative correlation [75]
NCBI, UCSC
GeneSplicer
program
EnsMart
Remove garbage EST, EST
coverage,
Negative correlation [65]
Riken’s
FANTOM3
Riken’s FANTOM3 BLAST
Positive correlation when
includes all gene fami-
lies. Negative correlation
within multigene families
[76]
C. elegans WormPep WormPep BLAST
Lower AS occurrence in
multigene families
[77]
Rice TIGR 4.0 PASA program BLASTP
Remove genes that lack
transcript evidence
Multigene families have
significantly higher AS
incidence than singletons
[78]
Arabidopsis TAIR7 TAIR7 TAIR7
Multigene families have
significantly higher AS
incidence than singletons
[78]
correlated to the number of new transcript isoforms and
proposed that the increase of gene expression breadth
is essential for acquiring new transcript isoforms, which
could be maintained by a new form of balancing selection.
Moreover, experimental and bioinformatics analyses have
shown that AS can generate a variety of functional mRNAs
and protein products, displaying distinct stability properties,
subcellular localization, and function [9] as well as in specific
stages in cell diﬀerentiation [82], sex diﬀerentiation [83, 84],
and development [9].
Single-gene studies have provided examples where alter-
native splicing can lead to functional innovation before
any events of gene duplication have taken place. One such
example is that of Troponin I (TnI), which plays a key
role in muscle contraction. In the vertebrate genome, TnI
exists in three copies each expressed in a diﬀerent muscle
type (skeletal, fast and slow, and cardiac). In Ciona, one
of the closest relatives of vertebrates TnI is present as a
single gene. Interestingly, however, the Ciona gene produces
three distinct alternatively spliced isoforms, each found to
resemble the expression profile of one of the vertebrate
genes suggesting that the specialisation of the TnI proteins
to function in each muscle type preceded gene duplication
events [85]. This pattern of alternative splice variants in
ancestrally single genes resembling expression profiles of
genes later duplicated has also been found in synapsin-2
genes in tetrapods [86] andMITF genes in teleost fish species
[87, 88]. These examples suggest that alternative splicing can
be a mechanism for functional innovation preceding events
of gene duplication through one of the three possible paths
(Figure 4).
Genes may also further gain alternative splicing and
regulation after duplication along with the complexity of
the organ systems after the divergence of protochordates
and vertebrates. Comparison between transcriptional factors
Pax genes in vertebrates and amphioxus has shown that at
least 52 reported alternative-splicing events in vertebrates
compared to 23 events in amphioxus [89]. Furthermore,
vertebrate Pax genes have maintained most of their ancestral
functions and also expanded their expression [90]. Novel
alternative splicing of Pax genes has been shown to modify
the functional domain content (e.g., DNA binding) and
transactivation capacities of the resulting protein products
[89]. For example, a novel alternative transcript of Pax3
can transactivate a cMET reporter construct in mouse [91].
These additional isoforms of Pax3 have been proposed to
play a functional role in the acquisition of new roles at
neural plate in vertebrates [89]. Similarly, vertebrate-specific
AS events of exon 5a in Pax4 and Pax6 have been linked
to functional roles in the development of vertebrate eye
[89, 92]. Therefore, it is reasonable to propose the hypothesis
that, besides gene duplication, alternative splicing plays
important roles in acquiring novel functions contributing to
the complexity of the organ systems after the divergence of
protochordates and vertebrates [93]. The potential roles of
the increasing prevalence of AS in vertebrates in functional
innovation will be largely explored in more gene families
or genomewide level in the future, which will further
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our understanding of how AS contributes to functional
innovation.
8. Conclusion
Here we have reviewed evidence from genomewide studies as
well as possible avenues for future comparatives studies for
the potential of alternative splicing as a source of functional
innovation during the evolution of the eukaryotic genome.
While it is now clear that AS is prevalent in the human
genome, obstacles still remain in the assessment how alter-
native splicing has evolved through time. The main obstacle
lies in that while most other genomic features can be directly
measured or estimated from genomic sequences alone, no
accurate estimates of alternative splicing can be obtained
from genomic sequence analysis. The reliance in transcript
sequences availability to measure AS together with the strong
bias brought by unequal transcript coverage has hampered
the genomewide assessment of AS in all but a few model
species and makes diﬃcult any direct comparison between
species. This has slowed down the study of how alternative
splicing has evolved over time, how AS is regulated, and how
it may relate to other genomic features and most crucially to
phenotype. The ever-increasing transcript profiling for many
more species combined with the use of comparable index
estimates will allow addressing a number of evolutionary
questions regarding the evolution of AS and its implications
for the evolution of transcript diversity and functional
innovation.
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